Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Brief Summary: This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person's white blood cells to kill melanoma cells. Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining aldesleukin with vaccine therapy is more effective than aldesleukin alone in treating melanoma.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine, Drug: Interferon Alfa-2b | Arm Label: B1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Arm Label: B2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): A1, A2, B1, B2 | Intervention Type: DRUG; Name: Fotemustine; Assigned to Arm(s): A1, A2 | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): A2, B2
B: Arm Label: Nivolumab, 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (Nivolumab), Drug: Placebo matching Dacarbazine | Arm Label: Dacarbazine, 1000 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo matching BMS-936558 (Nivolumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: BMS-936558 (Nivolumab); Assigned to Arm(s): Nivolumab, 3 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo matching BMS-936558 (Nivolumab); Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Placebo matching Dacarbazine; Assigned to Arm(s): Nivolumab, 3 mg/kg
C: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
D: Arm Label: Arm I (aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: gp100 Antigen, Drug: Montanide ISA 51 VG, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: BIOLOGICAL; Name: gp100 Antigen; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: DRUG; Name: Montanide ISA 51 VG; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)

Answer: D